Literature DB >> 16525857

Dose-dependent retrograde facilitation of verbal memory in healthy elderly after acute oral lorazepam administration.

Nunzio Pomara1, Thomas M Facelle, Amy E Roth, Lisa M Willoughby, David J Greenblatt, John J Sidtis.   

Abstract

RATIONALE: Retrograde facilitation (RF) refers to a paradoxical phenomenon in which recall of information presented before acute administration of agents generally associated with anterograde amnestic and sedative effects, such as benzodiazepines, is enhanced relative to a placebo condition. However, it is unclear whether this effect occurs in elderly individuals and if it is influenced by plasma drug levels, baseline cognitive function, or genetic factors such as the APOE e-4 allele, that may modulate drug-induced cognitive toxicity.
OBJECTIVES: To determine if acute oral doses of lorazepam (0.5 mg, 1 mg) produced RF in elderly individuals exposed to interference tasks, and the variables associated with RF.
MATERIALS AND METHODS: Sixty-four cognitively intact and highly educated (>12 years) older adults (mean age, 66.09 years) participated in a placebo-controlled double-blind crossover study. The Buschke Selective Reminding Test was used to assess RF and amnestic effects for verbal memory. Self-ratings of mood states were also obtained.
RESULTS: Lorazepam administration resulted in significant dose-dependent RF, i.e., better recall of pre-drug word lists compared to placebo [F(1,63)= 15.358; p<0.001 and F(1,63)= 46.163; p<0.001 for 0.5 and 1 mg lorazepam, respectively]. Also, more of the pre-drug words were recalled in the 1.0-mg-lorazepam condition relative to the 0.5-mg-lorazepam condition [F(1,63)=29.498; p<0.001]. In both the 0.5 and 1 mg lorazepam conditions, participants who exhibited high RF experienced significantly greater lorazepam-induced memory impairments over time [F(3,61)=2.901; p<0.05; F(3,61)=2.698; p<0.05; 0.5 and 1 mg lorazepam, respectively]. Also, in the 1-mg-lorazepam condition, participants who exhibited high RF reported significantly greater drowsiness relative to participants who showed less RF [t(62)=-2.521; p<0.05]. RF was not significantly associated with age, the APOE epsilon4 allele, years of education, global cognitive status, vocabulary scores, or a memory index score.
CONCLUSION: In healthy elderly, acute oral lorazepam administration resulted in dose-dependent RF, which was associated with greater anterograde amnestic and sedative effects.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16525857     DOI: 10.1007/s00213-006-0336-0

Source DB:  PubMed          Journal:  Psychopharmacology (Berl)        ISSN: 0033-3158            Impact factor:   4.415


  40 in total

1.  Conditions under which lorazepam can facilitate retrieval.

Authors:  S E File; E Fluck; E M Joyce
Journal:  J Clin Psychopharmacol       Date:  1999-08       Impact factor: 3.153

2.  Apolipoprotein E-epsilon4 genotype predicts a poor outcome in survivors of traumatic brain injury.

Authors:  G Friedman; P Froom; L Sazbon; I Grinblatt; M Shochina; J Tsenter; S Babaey; B Yehuda; Z Groswasser
Journal:  Neurology       Date:  1999-01-15       Impact factor: 9.910

3.  Declining brain activity in cognitively normal apolipoprotein E epsilon 4 heterozygotes: A foundation for using positron emission tomography to efficiently test treatments to prevent Alzheimer's disease.

Authors:  E M Reiman; R J Caselli; K Chen; G E Alexander; D Bandy; J Frost
Journal:  Proc Natl Acad Sci U S A       Date:  2001-03-13       Impact factor: 11.205

4.  Cerebral metabolic and cognitive decline in persons at genetic risk for Alzheimer's disease.

Authors:  G W Small; L M Ercoli; D H Silverman; S C Huang; S Komo; S Y Bookheimer; H Lavretsky; K Miller; P Siddarth; N L Rasgon; J C Mazziotta; S Saxena; H M Wu; M S Mega; J L Cummings; A M Saunders; M A Pericak-Vance; A D Roses; J R Barrio; M E Phelps
Journal:  Proc Natl Acad Sci U S A       Date:  2000-05-23       Impact factor: 11.205

5.  Apolipoprotein E epsilon4 allele and lorazepam effects on memory in high-functioning older adults.

Authors:  Nunzio Pomara; Lisa Willoughby; Keith Wesnes; David J Greenblatt; John J Sidtis
Journal:  Arch Gen Psychiatry       Date:  2005-02

6.  Hippocampal, amygdalar, and global brain atrophy in different apolipoprotein E genotypes.

Authors:  T den Heijer; M Oudkerk; L J Launer; C M van Duijn; A Hofman; M M B Breteler
Journal:  Neurology       Date:  2002-09-10       Impact factor: 9.910

7.  Increased anticholinergic challenge-induced memory impairment associated with the APOE-epsilon4 allele in the elderly: a controlled pilot study.

Authors:  Nunzio Pomara; Lisa M Willoughby; Keith Wesnes; John J Sidtis
Journal:  Neuropsychopharmacology       Date:  2004-02       Impact factor: 7.853

8.  New evidence on benzodiazepine use and falls: the time factor.

Authors:  C I Neutel; J P Hirdes; C J Maxwell; S B Patten
Journal:  Age Ageing       Date:  1996-07       Impact factor: 10.668

9.  Association of apolipoprotein E allele epsilon 4 with late-onset familial and sporadic Alzheimer's disease.

Authors:  A M Saunders; W J Strittmatter; D Schmechel; P H George-Hyslop; M A Pericak-Vance; S H Joo; B L Rosi; J F Gusella; D R Crapper-MacLachlan; M J Alberts
Journal:  Neurology       Date:  1993-08       Impact factor: 9.910

10.  Apolipoprotein E and cognitive change in an elderly population.

Authors:  B T Hyman; T Gomez-Isla; M Briggs; H Chung; S Nichols; F Kohout; R Wallace
Journal:  Ann Neurol       Date:  1996-07       Impact factor: 10.422

View more
  2 in total

1.  Heavy use versus less heavy use of sedatives among non-medical sedative users: Characteristics and correlates.

Authors:  Prasanthi Nattala; Kit Sang Leung; Arbi Ben Abdallah; Linda B Cottler
Journal:  Addict Behav       Date:  2010-09-25       Impact factor: 3.913

2.  A study on the specificity of the association between hippocampal volume and delayed primacy performance in cognitively intact elderly individuals.

Authors:  Davide Bruno; Michel J Grothe; Jay Nierenberg; Henrik Zetterberg; Kaj Blennow; Stefan J Teipel; Nunzio Pomara
Journal:  Neuropsychologia       Date:  2015-01-19       Impact factor: 3.139

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.